Tibotec reveals TMC435 data

Tibotec has announced new interim clinical data showing antiviral activity of TMC435, an investigational protease inhibitor for chronic hepatitis C virus infection. In interim findings from the first 28 days of treatment for the first cohort of 50 treatment naive HCV+, genotype 1 patients, both doses showed dose-dependent antiviral activity. Additional data will be presented at the American Association for the Study of Liver Disease's Liver Meeting 2008 in San Francisco.

"Tibotec is committed to evaluating the safety and efficacy of TMC435 in clinical studies to determine its potential use in people with HCV," said Roger Pomerantz, M.D., president of Tibotec Research and Development. "This is an important step in our mission of addressing treatment challenges of infectious diseases, including HCV, HIV and tuberculosis."

- see Tibotec's release

PLUS: CuraGen announced preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Release

ALSO: Early data from a Phase II trial GlobeImmune's HCV drug GI-5005 show that the drug doubled viral clearance overall and in all major subgroups and doubled the rapid virologic response rate in naïve patients with high viral load. Release